Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life-sciences and other industries, recently executed
a contract services agreement with a well-known biotherapeutics firm. An
article discussing the company reads, “Under the terms of the agreement, the
firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to
enhance the process manufacturing of one of its candidate protein drugs (http://ibn.fm/aidN2). . . .
PBIO’s BaroFold technology platform offers a unique and cost-effective way to
address the complex and often-challenging process of manufacturing the
recombinant proteins that are required in the development of protein-based drugs.
Two of the major challenges associated with manufacturing recombinant proteins
are (1) the formation of aggregates and (2) protein misfolding. These are
significant issues that can prevent a protein drug candidate from ever making
it to market.”
To view the full article, visit http://ibn.fm/dKrgU
About Pressure BioSciences Inc.
Pressure BioSciences (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life-sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a
patented-enabling technology platform that uses alternating cycles of
hydrostatic pressure between ambient and ultra-high levels to safely and
reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule
extraction). PBIO’s primary focus is in the development of PCT-based products
for biomarker and target discovery, drug design and development,
biotherapeutics characterization and quality control, soil and plant biology,
forensics and counter-bioterror applications. Additionally, major new market
opportunities have emerged in the use of the company’s pressure-based
technologies in the following areas: (1) the use of its recently acquired
PreEMT technology from BaroFold Inc. to allow entry into the
biologics-contract, research-services sector, and (2) the use of its recently
patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible
fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized,
extended shelf-life or room-temperature stable, low-acid liquid foods that
cannot be effectively preserved using existing nonthermal technologies. For
more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
